Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Leukemia 4Breast Neoplasms 4Philadelphia Chromosome 3Neoplasms 3Neoplasm Metastasis 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Translocation, Genetic 1Thymus Neoplasms 1Thymoma 1Pathologic Processes 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Mesothelioma 1Leukemia, Myeloid, Chronic-Phase 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1Blast Crisis 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 44fludarabine phosphate 40Busulfan 32Tacrolimus 27Filgrastim 26Methotrexate 24Cytarabine 24Cyclosporine 23Antilymphocyte Serum 22Radiotherapy 20Mycophenolic Acid 19Whole-Body Irradiation 18Etoposide 18Imatinib Mesylate 17Methylprednisolone 15Melphalan 13Cord Blood Stem Cell Transplantation 10sargramostim 9Thiotepa 9fludarabine 8Psychiatric Rehabilitation 8Dasatinib 8Topotecan 7Therapeutics 7Prednisone 7Flow Cytometry 7Decitabine 7Carboplatin 7merphos 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Blast Crisis × bosutinib × Clear all
NCT02311998 2023-07-17

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

M.D. Anderson Cancer Center

Phase 1/2 Completed
22 enrolled 14 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡